Medigus Surges Most in Four Months on FDA Approval Request

Medigus Ltd. (MDGS) surged the most in more than four months after the company said it will seek U.S. Food and Drug Administration approval to market its SRS device for the treatment of gastro-esophageal reflux disease.

Shares of the maker of endoscopic procedures and devices rallied 16 percent, the most since Sept. 11, to 0.698 shekel at 10:38 a.m. in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.